Distinct signaling mechanisms activate the target of rapamycin in response to different B‐cell stimuli
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Phosphoinositide 3‐kinase (PI3K) and the mammalian target of rapamycin (mTOR), a downstream kinase, are both required for proliferation of splenic B cells. However, the functions of PI3K and mTOR in response to different stimuli and among B cell subsets have not been fully elucidated. We used flow cytometry and magnetic cell sorting to examine the requirement for PI3K and mTOR in responses of splenic B cell subsets to BCR and LPS stimulation. BCR‐mediated phosphorylation of Akt and Erk is sensitive to the PI3K catalytic inhibitor wortmannin in both marginal zone (MZ) and follicular (FO) cells. BCR‐mediated mTOR activation in both subsets is inhibited by wortmannin, though less strongly in MZ cells. In contrast, LPS‐induced mTOR signaling is strikingly resistant to wortmannin in both subsets. Similarly, functional responses to LPS are partially wortmannin resistant yet sensitive to mTOR inhibition by rapamycin. We also observed mitogen‐independent mTOR activity that is regulated by nutrient availability, and is significantly elevated in MZ cells relative to FO cells. These data define both similarities and differences in PI3K/mTOR signaling mechanisms in MZ and FO cells, and suggest that mTOR signaling can occur in the absence of PI3K activation to promote B cell responses to LPS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174
Phosphatidic Acid-Mediated Mitogenic Activation of mTOR Signaling
Fang, Y., Vilella-Bach, M., Bachmann, R., Flanigan, A., & Chen, J. (2001) · Science · doi:10.1126/science.1066015 · Cited by 1,055
Cited by
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
“…(Donahue and Fruman, 2007) and later in CD8 + T cells (Salmond et al., 2009). mTORC1 activity in B cells is highly dependent on nutrients in vitro (Donahue and Fruman, 2007; Wlodarski et al., 2005) and suppressed under hypoxic conditions in germinal centers (Cho et al., 2016; Jellusova et al.,…”
InfluentialSelf-citationImmunoregulatory functions of mTOR inhibition
Thomson, A. W., Turnquist, H. R., & Raimondi, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2546 · Cited by 847
Regulation of Immune Responses by mTOR
Powell, J. D., Pollizzi, K. N., Heikamp, E. B., & Horton, M. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075024 · Cited by 836
Zeng, H., Cohen, S., Guy, C., Shrestha, S., Neale, G., Brown, S. A., Cloer, C., Kishton, R. J., Gao, X., Youngblood, B., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.017 · Cited by 345
The multiple facets of mTOR in immunity
Weichhart, T., & Säemann, M. D. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.02.002 · Cited by 259
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances
So, L., & Fruman, D. A. (2012) · Biochemical Journal · doi:10.1042/bj20112092 · Cited by 218
Self-citationImproving the efficacy and safety of biologic drugs with tolerogenic nanoparticles
Kishimoto, T. K., Ferrari, J. D., LaMothe, R. A., Kolte, P. N., Griset, A. P., O'Neil, C., Chan, V., Browning, E., Chalishazar, A., Kuhlman, W., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.135 · Cited by 201
mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition
Limon, J. J., So, L., Jellbauer, S., Chiu, H., Corado, J., Sykes, S. M., Raffatellu, M., & Fruman, D. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407104111 · Cited by 76
“Although AKT can promote mTORC1 activity (multiple arrows), inhibition of PI3K/AKT does not completely suppress mTORC1 signaling in activated B cells (36).”
BackgroundSelf-citation
Metadata
- Authors
- Donahue, A. C., & Fruman, D. A.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2007-09-26
- Volume
- 37
- Issue
- 10
- Pages
- 2923-2936
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W2006974350
- Cited by
- 82
- References
- 3
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.